An NCI-designated Consortium Cancer Center
|
|
|
Weekly Research Newsletter
|
Week of November 28, 2022
|
|
|
| Joseph A. Califano III, M.D. Appointed Director of Moores Cancer Center
Following a comprehensive national search, Dr. Califano succeeds Scott Lippman, M.D., who announced in November 2021 that he would step down as MCC Director to lead the PreCancer Genome Atlas project. Dr. Califano brings immense experience and expertise to the position, having served as MCC Physician-in-Chief, Director of the Hanna and Mark Glieberman Head and Neck Cancer Center, and Co-Leader of the MCC Structural and Functional Genomics Program. Dr. Califano will transition from these duties to center his attention on the MCC directorship. Congratulations, Dr. Califano.
|
|
|
| Dr. Lawrence Goldstein, Distinguished Stem Cell Researcher, to Receive the Revelle Medal
Dr. Goldstein was instrumental in founding the UC San Diego Stem Cell Program, the Sanford Consortium for Regenerative Medicine, and the Sanford Stem Cell Clinical Center. This week, he will receive the Revelle Medal, which recognizes sustained, distinguished, and extraordinary service to the campus. Indeed, Dr. Goldstein's achievements are illustrative of UC San Diego founder Roger Revelle’s vision to attract distinctive and visionary faculty leaders. For Dr. Goldstein, the medal will honor a record of accomplishment that advances UC San Diego in fulfilling the campus mission of exceptional teaching, research, service, and patient care. Congratulations, Dr. Goldstein.
|
|
|
Parsing the Genetic Drivers of Head and Neck Cancers
Although human papilloma virus causes some cases of head and neck cancer, the most lethal form of head and neck cancer is linked to chromosomal alterations. A new study sharpens that association and hints of more effective treatment options. To learn more, click the blue button below.
|
|
|
Newfound Cancer Cell Biology Suggests Which Patients Will Respond to Immunotherapy
Patients with head and neck cancer who exhibit more genetic material on chromosome 9 in their cancer cells survive three times longer after receiving immunotherapy than those exhibiting less genetic material at that location, a new study finds. Led by researchers from NYU Grossman School of Medicine and UC San Diego, Moores Cancer Center, this new study targets the human immune system, which can recognize cancer cells as abnormal and attack them. To learn more, click the blue button below.
|
|
|
Join the Work in Progress Seminar Series
Please join MCC's standing Work in Progress Seminar Series every first Wednesday of the month. If you are interested in presenting or joining, the please contact Program Coordinator, Diana Arroyo at d1arroyo@health.ucsd.edu.
|
|
|
Highlights from The Cancer Letter |
NCI Directors Report - Dr. Douglas Lowy: NCI to Target Multi-Cancer Detection Tests, Diversity in Workforce, and Clinical Trials
Read full article on page 18 of The Cancer Letter, volume 48, number 32.
|
|
|
|
Pharmacology Seminar Series
Circadian Clocks, Glial Regulation, and Neurodegenerative Diseases
Tuesday, November 29, 2022 at 12:00 p.m. PT
Leichtag Biomedical Research Building (Room 107)
Optional Webinar Registration
Erik S. Musiek, M.D., Ph.D.
Charlotte & Paul Hagemann Professor
Department of Neurology
Washington University School of Medicine
Hosted by William Joiner, Ph.D.
Questions? Contact pharmeducation@health.ucsd.edu
|
|
|
|
49th Annual MilliporeSigma-UCSD Lectureship Series
Lipid Nanoparticles: From Model Membranes to COVID Vaccines and Gene Therapies
Wednesday, November 30, 2022 at 4:00 p.m.
Fifty Years of Lipids and How That Led to the Lipid Nanoparticles Enabling the COVID-19 mRNA Vaccines
Thursday, December 1, 2022 at 4:00 p.m.
Lipid Nanoparticles That Enable Gene Therapies: The Next Generation of Pharmaceuticals
Health Sciences Education Center Auditorium, Lower Level, Skaggs School of Pharmacy & Pharmaceutical Sciences Building, UC San Diego
Refreshments at 3:30 p.m. both days. Reception following Wednesday lecture.
Pieter Cullis, Ph.D.
Director, Nanomedicines Research Group
Professor, Department of Biochemistry and Molecular Biology University of British Columbia
|
|
|
|
Division of Regenerative Medicine Seminar Series
Toward Practical Justice in the Inequitable Biotechnology Revolution
Monday, December 5, 2022 from 12:00 p.m. to 1:00 p.m.
Sanford Consortium for Regenerative Medicine
Conference Room 1013
2880 Torrey Pines Scenic Dr.
La Jolla, CA 92037
Optional Zoom Link
Ubaka Ogbogu, LL.B., B.L., LL.M., S.J.D.
Professor and Associate Dean of Research, Faculty of Law
Chair, Research Ethics Board 2
Katz Research Fellow in Health Law and Science Policy
University of Alberta
Hosted by Rob Signer, Ph.D.
|
|
|
|
Cancer Control Program, Work in Progress Seminar Series
Colorectal Cancer Disparities across Latin America: A Mortality Trend Analysis from 1990 to 2019
Wednesday, December 14, 2022 at 12:00 p.m.
Hybrid Meeting (In-Person/Virtual)
Moores Cancer Center, 2nd Floor
Comer Commons Conference Room
Zoom Link
Raphael Guimaraes, Ph.D.
Visiting Associate Researcher
Herbert Wertheim School of Public Health & Human Longevity Science
|
|
|
|
Solid Tumor Therapeutics Program
S1609 DART: Lessons Learned in Rare Tumor Immunotherapy
Wednesday, December 14, 2022, from 4:30 p.m. to 5:30 p.m.
Location Forthcoming
Sandip Patel, M.D.
Professor, Medical Oncology
Leader, Experimental Therapeutics
Director, Clinical Trials Office
UC San Diego
Deputy Director
San Diego Center for Precision Immunotherapy
|
|
|
COMMUNITY OUTREACH AND ENGAGEMENT
|
| |
Vaccination Communication: Inoculating Against Misinformation
December 6, 2022 from 12:00 to 1:00 p.m.
UC San Diego Moores Cancer Center (MCC) is partnering with the California Immunization Coalition (CIC) to host this webinar to address not only the threat of vaccine mis- and disinformation on social media, but also the urgency for health care organizations and professionals to communicate effectively through social media platforms with trusted messengers.
Speakers: Todd Wolynn, M.D., MMM and Alex McDonald, M.D., FAAFP, CAQSM
The conversation will be moderated by UC San Diego MCC Community Outreach & Engagement Coordinator, Margaux Stack-Babich, M.P.H. and CIC Board member Eric Ball, M.D., FAAP, Southern Orange County Pediatric Associates CHOC Children's Primary Care Network.
|
|
|
New Community Outreach and Engagement (COE) Newsletter
We are thrilled to share our first quarterly COE newsletter! Please take a moment to read Elena Martinez's welcome message and make a note of COE resources and upcoming events.
|
|
|
CT2 2022-2023 Lecture Series
MRTX0902: A SOS1 inhibitor for therapeutic intervention of KRAS-driven cancers
Monday, November 28, 2022 from 12:00 p.m. to 1:00 p.m.
In-Person and Virtual
Moores Cancer Center, 2nd Floor, Comer Commons
Zoom Link
Jacob Haling, Ph.D.
Director of Biology
Mirati Therapeutics
|
|
|
Student Volunteers Available
Cancer Research, Training, and Education Coordination (CRTEC) has identified three motivated undergraduate students who are interested in volunteering in a lab at MCC. This is a win-win research experience for the students and your lab. Please contact Amy Spilkin, Ph.D. (aspilkin@health.ucsd.edu), if you would like to connect with one or more of these students:
|
- Third-year UCSD undergraduate majoring in Biology, minoring in Math
- Second-year UCSD premed undergraduate majoring in Human Biology
-
First-year UCSD undergraduate majoring in Cognitive and Behavioral Neuroscience
|
CRTEC administration will complete all necessary paperwork for these student volunteers.
|
|
|
Speed Mentoring Workshop, Faculty Sign Ups
Faculty Members of MCC are invited to serve a mentors at the MCC Speed Mentoring Workshops, organized by MCC Cancer Research, Training, and Education Coordination (CRTEC). These workshops serve not only undergraduate, graduate, and post-graduate students, but also project scientists, and research scientists, and junior faculty. Please select the session(s) for which are are available to mentor, and please select all that apply. You will be scheduled for only one of the dates that you choose—providing several dates merely helps to coordinate schedules. You will be contacted with a confirmation of the schedule.
CRTEC Speed Mentoring takes place on the second Thursday of each month from 12:00 p.m. to 1:00 p.m. on Zoom. Participating faculty members will receive 1 hour of mentorship credit, approved by MCC leadership.
|
|
|
HIGHLIGHTED FUNDING OPPORTUNITIES
|
|
|
NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Required)
NCI intends to commit $2.7 M in FY 2023 to fund up to 16 awards submitted for this FOA or its companion FOAs; the total project period may not exceed 5 years.
Postdocs interested in applying must submit a letter of intent (LOI) to Amy Spilkin, Ph.D. (aspilkin@health.ucsd.edu) as a single PDF by the internal deadline of December 2 at 5:00 p.m., in accordance with the instructions below:
|
- Letter of intent / Research statement
- Ariel font (at least 11-point), at least 1/2-inch top and side margins, 1 page maximum, including any figures, tables, etc. Citations may be included only on a second page.
-
Include your name, degree(s), postdoc year, mentor, phone number, email address; the specific grant and scientific area to which you are applying; statement of your eligibility per guidelines; and project title.
- Briefly describe your background, goals, and objectives; plan for career development; and research strategy.
- Biosketch in current NIH format
-
5 pages maximum; include active and pending support
- Your LOI submission is NOT complete until you have received an acknowledgment of receipt.
|
Internal Deadline: December 2, 2022 at 5:00 p.m.
|
| |
NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Basic Experimental Studies with Humans Required)
NCI intends to commit $2.7 M in FY 2023 to fund up to 16 awards submitted to this FOA or its companion FOAs: the total project period may not exceed 5 years.
Postdocs interested in applying must submit a letter of intent (LOI) to Amy Spilkin, Ph.D. (aspilkin@health.ucsd.edu) as a single PDF by the internal deadline of December 2 at 5:00 p.m., in accordance with the instructions below:
|
- Letter of intent / Research statement
- Ariel font (at least 11-point), at least 1/2-inch top and side margins, 1 page maximum, including any figures, tables, etc. Citations may be included only on a second page.
-
Include your name, degree(s), postdoc year, mentor, phone number, email address; the specific grant and scientific area to which you are applying; statement of your eligibility per guidelines; and project title.
- Briefly describe your background, goals, and objectives; plan for career development; and research strategy.
- Biosketch in current NIH format
-
5 pages maximum; include active and pending support
- Your LOI submission is NOT complete until you have received an acknowledgment of receipt.
|
Internal Deadline: December 2, 2022 at 5:00 p.m.
|
|
|
NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Not Allowed)
NCI intends to commit $2.7 M in FY 2023 to fund up to 16 awards submitted to this FOA or its companion FOAs; the total project period may not exceed 5 years.
Postdocs interested in applying must submit a letter of intent (LOI) to Amy Spilkin, Ph.D. (aspilkin@health.ucsd.edu) as a single PDF by the internal deadline of December 2 at 5:00 p.m., in accordance with the instructions below:
|
- Letter of intent / Research statement
- Ariel font (at least 11-point), at least 1/2-inch top and side margins, 1 page maximum, including any figures, tables, etc. Citations may be included only on a second page.
-
Include your name, degree(s), postdoc year, mentor, phone number, email address; the specific grant and scientific area to which you are applying; statement of your eligibility per guidelines; and project title.
- Briefly describe your background, goals, and objectives; plan for career development; and research strategy.
- Biosketch in current NIH format
-
5 pages maximum; include active and pending support
- Your LOI submission is NOT complete until you have received an acknowledgment of receipt.
|
Internal Deadline: December 2, 2022 at 5:00 p.m.
|
|
|
Department of Defense (DoD) Breast Cancer Research Program (BCRP), Clinical Research Extension Award (CREA)
Three expected awards; estimated total program funding $26,400,000
The FY22 DoD BCRP CREA aims to extend the data collection, follow-up, and analysis of breast cancer clinical research studies. The goal of this award is to increase the clinically relevant effect of breast cancer patient participation in clinical research by addressing the knowledge lost due to limited or early termination of patient follow-up and sample collection and analysis. The award may not be used to support a clinical trial directly.
Deadline: December 13, 2022
|
|
|
Advancing Head and Neck Cancer Early Detection Research (AHEAD)
Maximum funding $500,000 direct costs/year for 5 years.
The purpose of this Funding Opportunity Announcement (FOA) is to accelerate translation of research to improve early detection of head and neck cancers (HNC). This FOA seeks applications that target early detection of HNC by (1) applying molecular, cellular, and multi-omics signatures to clinical studies for differentiating benign from premalignant lesions and (2) identifying prognostic signatures on the transformation from premalignant to malignant lesions.
Deadline: January 27, 2023 at 5:00 p.m.
|
|
|
2023 ACTRI Pilot Projects – Community Research Partnership
These UCSD, Altman Clinical and Translational Research Institute (ACTRI) grants are (1) 1-year competitive awards (up to $30,000) to provide funding for early-stage projects and (2) available to all ACTRI members with faculty appointments; funding priority is given to early-career faculty.
Requests for assistance with identifying potential community or academic partners: October 2022 - November 2022
Deadline: Friday, February 24, 2023 by 2:00 p.m. PT
|
|
|
American Cancer Society (ACS) Request for Applications (RFA): Pilot and Exploratory Projects in Palliative Care of Cancer Patients and Their Families
The development of the palliative medicine speciality is a necessary step in addressing the unmet needs of both patients with serious illness and their families.
Pilot data typically are needed before funding agencies (e.g., NIH, VA, and ACS) will consider funding a research project. To support clinician investigators conducting patient-oriented research in palliative care, the ACS, in parallel with the National Palliative Care Research Center (NPCRC), is soliciting applications for pilot/exploratory research grants in palliative care for cancer patients and their families. These grants will generate the pilot data necessary to maximize an investigator's chances of successfully competing for larger grants.
This RFA is limited to applications that feature palliative care research projects for seriously ill cancer patients and their families in the following three areas:
|
-
Exploring the relationship of pain and other distressing symptoms on quality and quantity of life, independence, function, and disability and developing interventions directed at their treatment in patients with advanced and chronic illnesses;
- Studying methods of improving communication between cancer survivors living with serious illness with their families and health care providers;
-
Evaluating models and systems of care for patients living with advanced illness and their families.
|
|
|
OTHER FUNDING OPPORTUNITIES
|
|
|
Damon Runyon, Physician-Scientist Training Award
Award: Total of $460,000, distributed over 4 years
Deadline: December 1, 2022 at 4:00 p.m. ET
|
|
|
Alex's Lemonade Stand 2023 Young Investigator Grant
This grant offers up to $50,000 in direct costs per year for 3 years
Deadline: December 12, 2022 at 8:00 p.m. ET
|
|
|
Basic/Translational Research on Health Disparities Among Underrepresented People Living with HIV (PLWH) and Cancer (R01 Clinical Trial Not Allowed)
NCI intends to commit $3.5M in FY 2023 to fund 7-10 awards and $3.5M in FY 2024 to fund another 7-10 awards.
Deadline: December 15, 2022 at 5:00 p.m. PT
|
|
|
Basic/Translational Research on Health Disparities in Underrepresented People Living with HIV (PLWH) and Cancer (R21 Clinical Trial Not Allowed)
The combined budget for direct costs for the 2-year project period may not exceed $275,000; no more than $200,000 may be requested in any single year; the maximum project period is 2 years.
Deadline: December 15, 2022 at 5:00 p.m. PT
|
| Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (U54 Clinical Trial Optional)
Budgets are limited to $2 million in direct costs per year for partnerships of two institutions and $2.5 million in direct costs per year for partnerships of three institutions; maximum duration 5 years.
Deadline: January 6, 2023 at 5:00 p.m. PT; LOI due 30 days prior
|
| Feasibility Studies to Build Collaborative Partnerships in Cancer Research (P20 Clinical Trial Not Allowed)
The combined budget for ISUPS and CC cannot exceed $375,000 in direct costs per year; maximum duration 4 years.
Deadline: January 6, 2023 at 5:00 p.m. PT; LOI due 30 days prior
|
|
|
Precompetitive Collaboration on Liquid Biopsy for Early Cancer Assessment: Liquid Biopsy Research Laboratories (U01 and U24)
U01 Award: $600,000 direct costs per year for 5 years
U24 Award: $450,000 direct costs per year for 5 years
Deadline: January 10, 2023 at 4:00 p.m. ET
|
| NCI Cancer Screening Research Network: Coordinating and Communication Center (UG1 Clinical Trial Required)
NCI intends to commit $1.5M in FY 2024 to fund 1 award; $2M is expected to be allocated per year in subsequent years for the CCC; maximum project period is 4 years.
LOI Deadline: January 28, 2023
Application Deadline: February 28, 2023
|
| NCI Cancer Screening Research Network: Statistics and Data Management Center (UG1 Clinical Trial Required)
NCI intends to commit $1M in FY 2024 to fund 1 award. $2M is expected to be allocated per year in subsequent years for the SDMC; maximum project period is 4 years.
LOI Deadline: January 28, 2023
Application Deadline: February 28, 2023
|
|
|
NCI Cancer Screening Research Network: ACCrual, Enrollment, and Screening Sites (ACCESS) Hub (UG1 Clinical Trial Required)
NCI intends to commit $8M in FY 2024 to fund 10-15 awards. $9M is expected to be allocated per year in subsequent years for ACCESS Hubs; requested budget must not exceed $750,000 in direct costs per year; maximum project period is 4 years.
LOI Deadline: January 28, 2023
Application Deadline: February 28, 2023
|
| Damon Runyon, Clinical Investigator Award
Award: $600,000 award for 3 years, distributed as $200,000 per year.
Deadline: February 1, 2023 at 4:00 p.m. ET
|
|
Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)
Maximum budget $375,000 direct costs/year for 5 years; NIH R01 standard due dates apply.
Deadline: February 5, 2023 at 5:00 p.m.
|
|
|
Coordinating Center for Cannabis and Cannabinoid Use Among Adult Cancer Patients During Treatment: Assessing Benefits and Harms (U24 Clinical Trial Not Allowed)
Limited $500,000 direct costs per year; maximum project period is 5 years.
Deadline: February 17, 2023 at 5:00 p.m. PT
|
|
Cannabis and Cannabinoid Use in Adult Cancer Patients During Treatment: Assessing Benefits and Harms (U01 Clinical Trial Not Allowed)
$500,000 direct costs per year; maximum project period is 5 years.
Deadline: February 18, 2023 at 5:00 p.m. PT
|
|
Notice of Special Interest (NOSI): Administrative Supplement for NCI Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT)
One CAP-IT DRCC will be awarded with a maximum total cost of $800,000 per year (maximum direct cost is $480,000 per year) in fiscal year 2023; at least 1 full year on the parent grant must remain at the time of funding; application budget is limited to 4 years.
Deadline: February 28, 2023
|
|
|
Pfizer-Cell Signaling, San Diego Postdoctoral and Graduate Fellowships
Postdoctoral Fellowship - $70,000 for postdoctoral salary and benefits
Graduate Fellowship - $46,000 for tuition in full and balance towards stipend
MCC is delighted to announce a new partnership with Pfizer Oncology to support one postdoctoral fellow and one graduate student for up to 2 years. Please see the RFA link below. The deadline to receive application materials (as a single PDF) is Monday, November 28, 2022. MCC encourages submissions from postdocs and graduate students in your labs who are working in the area of cell signaling and oncology. This is a remarkable opportunity for trainees to interact with the Pfizer Oncology team in La Jolla.
Deadline: November 28, 2022
|
|
|
Pink Shabbat Weekend
December 2-4, 2022
This weekend is about encouraging our members to think about their health in a positive way and improve the lives of our congregants and families who are living with or have an increased genetic risk for breast cancer. Let us help raise awareness for breast cancer.
Events will include pink parve challah fundraiser for breast and ovarian cancer research, campfire shabbat dinner and service, pink shabbat service, and a panel discussion facillitated by Moores Cancer Center.
|
|
|
3rd Annual Roger Tsien Cell Signaling Symposium
December 6, 2022 from 1:00 p.m. to 6:00 p.m.
Sanford Consortium, Roth Auditorium
2880 Torrey Pines Scenic Drive, La Jolla, CA 92037
Register Here
1:00 p.m. to 3:00 p.m. - Junior Faculty Talks
3:00 p.m. to 4:00 p.m. - Roger Tsien Lecture
4:00 p.m. to 6:00 p.m. - Poster Session and Reception
Questions? Email cellsigsd@health.ucsd.edu
|
|
|
Saturday, January 28, 2023
|
|
|
Newly Opened Clinical Trials
|
|
|
SHARED RESOURCE SPOTLIGHT
|
|
|
|
The MCC Microscopy Shared Resource provides access to a wide array of equipment and services, which include not only regular epifluorescence, bright field, deconvolution, and confocal microscopy, but also specialized methods such as total internal reflection fluorescence (TIRF) and super resolution imaging. In addition, in vivo live animal imaging using the IVIS 200 imaging system permits non-invasive monitoring of cancer progression, gene expression patterns, cell trafficking, drug delivery, and treatment. Major equipment and capabilities include the following:
|
|
|
Nikon A1R Laser Scanning Confocal / TIRF / STORM System
|
- High-resolution and high-speed multidimensional confocal imaging, photo activation and bleaching, FRET, and FRAP
- Fast live-cell imaging in TIRF mode
- Super resolution (20 to 50 nm resolution) using stochastic optical reconstruction (STORM) and photo activation localization microscopy (PALM)
|
Keyence BZ-X700 Fluorescence Microscope
|
- Automated brightfield and fluorescence microscopy
-
Fast multi-channel X-Y stitching and Z acquisition
- Sensitivity ranging from the UV to the far red (800 nm)
|
IVIS 200 Whole Animal Imaging System
|
- Bioluminescence and fluorescence imaging in living animals (GFP, RFP, Cy5.5 ICG)
|
- Basic analysis tools such as segmentation, counting, and quantification; advanced Ai tools for automated denoising and image clarification
- 2D and 3D object measurement and tracking tools and deconvolution
|
|
|
-
Li FL, Fu V, Liu G, Tang T, Konradi AW, Peng X, Kemper E, Cravatt BF, Franklin JM, Wu Z, Mayfield J, Dixon JE, Gerwick WH (STT), Guan KL (CBS). Hippo pathway regulation by phosphatidylinositol transfer protein and phosphoinositides. Nat Chem Biol. 2022 OCT 01; 18(10):1076-1086.
- Wang CP, McKinley M, Gomez SL, Gupta S (CCP), Itzkowitz SH, Shah SC (CCP). Socioeconomic status and ethnic enclave as risk factors for gastric adenocarcinoma in Hispanic and Asian Americans, a CCR analysis. Clin Gastroenterol Hepatol. 2022 OCT 21;
- Georges RO, Sepulveda H, Angel JC, Johnson E, Palomino S, Nowak RB, Desai A (CBS), López-Moyado IF, Rao A (SFG). Acute deletion of TET enzymes results in aneuploidy in mouse embryonic stem cells through decreased expression of Khdc3. Nat Commun. 2022 OCT 20; 13(1):6230.
- Pagadala MS, Lynch J, Karunamuni R, Alba PR, Lee KM, Agiri FY, Anglin T, Carter H (SFG), Gaziano JM, Jasuja GK, Deka R, Rose BS, Panizzon MS, Hauger RL, Seibert TM (STT). Polygenic risk of any, metastatic, and fatal prostate cancer in the Million Veteran Program. J Natl Cancer Inst. 2022 OCT 28
|
|
|
To submit any announcements, funding opportunities, events, or other important items to the newsletter, please utilize the submission form link below.
Please direct any questions to our Marketing and Communications Coordinator, Sarah Christie, at sjchristie@health.ucsd.edu
|
|
|
|
Want to be highlighted in the Moores Cancer Center newsletter or on the MCC website?
We want to know and share in all of our successes at MCC. To that end, we have created a pipeline for our members to share recent publications, awards, new appointments, and research highlights that you would like to see in our MCC weekly newsletter or on the website. Please provide us with the data we need to showcase your great work by completing the Member Survey linked below.
We sincerely thank you in advance for your time!
|
|
|
Moores Cancer Center (MCC) is not only one of only 52 National Cancer Institute (NCI)-designated comprehensive cancer centers in the nation, but also the only one providing multidisciplinary, research-driven detection, treatment, survivorship, and prevention of cancer in San Diego County. The 360 MCC member scientists and clinicians hail from 22 UC San Diego specialty departments, Rady Children’s Hospital, San Diego State University, and the La Jolla Institute of Immunology.
With strengths in stem cell research, immune-oncology, precision medicine, cancer disparities, and pre-cancer and risk research, MCC investigators address translational oncology and drug development through partnerships with biotechnology and pharmaceutical companies. MCC was founded and received its NCI designation in 1978.
|
|
|
Department of Research Administration
|
|
|
Manage your preferences | Opt Out using TrueRemove™
Got this as a forward? Sign up to receive our future emails. View this email online.
|
3855 Health Sciences Drive MC 0698 | La Jolla, CA 92093 US
|
|
|
This email was sent to sjchristie@ucsd.edu.
To continue receiving our emails, add us to your address book.
|
|
|
|